GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » Total Current Liabilities

Renovacor (Renovacor) Total Current Liabilities : $8.43 Mil (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Renovacor Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Renovacor's total current liabilities for the quarter that ended in Sep. 2022 was $8.43

Renovacor Total Current Liabilities Historical Data

The historical data trend for Renovacor's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor Total Current Liabilities Chart

Renovacor Annual Data
Trend Dec20 Dec21
Total Current Liabilities
0.19 4.03

Renovacor Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only 3.69 4.03 3.40 4.13 8.43

Renovacor Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Renovacor's Total Current Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.752+0
+Other Current Liabilities+Current Deferred Liabilities
=1.282+0
=4.03

Renovacor's Total Current Liabilities for the quarter that ended in Sep. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=5.187+1.26
+Other Current Liabilities+Current Deferred Liabilities
=1.986+0
=8.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Renovacor Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Renovacor's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovacor (Renovacor) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » Total Current Liabilities
Comparable Companies
ONCS SYN ACER CNTX APTX IDRA VINC GLTO VTVT INTI OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
P.O. Box 8142, Greenwich, CT, USA, 06836
Website
https://www.renovacor.com
Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Executives
Joseph S Carroll officer: Chief Accounting Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino director C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau director C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr. director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll officer: Chief Financial Officer
Jonas Grossman director 17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa director 17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook director, officer: Chief Executive Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen officer: Chief Scientific Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran officer: Chief Medical Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco officer: Interim CFO

Renovacor (Renovacor) Headlines

From GuruFocus

SHAREHOLDER ALERT: Weiss Law Reminds LFG, ECOM, LOTZ, and RCOR Shareholders About Its Ongoing Investigations

By PRNewswire PRNewswire • 11-03-2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, RCKT, RMED, RCOR

By PRNewswire PRNewswire • 10-28-2022

RENOVACOR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Renovacor, Inc. - RCOR

By PRNewswire PRNewswire • 10-21-2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMBC, BTRS, LOGC, RCOR

By Value_Insider Value_Insider • 10-23-2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCOR, SMBC, TALO, BTRS

By PRNewswire PRNewswire • 11-15-2022

EQUITY ALERT: The M&A Class Action Firm Continues Investigating the Merger � RCOR, TALO, PEBO, SMBC

By Value_Insider Value_Insider • 11-01-2022

RENOVACOR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Renovacor, Inc. - RCOR

By PRNewswire PRNewswire • 11-03-2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCOR, SMBC, TALO

By PRNewswire PRNewswire • 11-02-2022

SHAREHOLDER ALERT: Weiss Law Reminds RCOR, BTRS, AERC, and AKUS Shareholders About Its Ongoing Investigations

By PRNewswire PRNewswire • 11-11-2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCKT, RCOR, SMBC, TALO

By PRNewswire PRNewswire • 11-10-2022